194 related articles for article (PubMed ID: 15893725)
1. Structural basis for an unexpected mode of SERM-mediated ER antagonism.
Wu YL; Yang X; Ren Z; McDonnell DP; Norris JD; Willson TM; Greene GL
Mol Cell; 2005 May; 18(4):413-24. PubMed ID: 15893725
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
4. Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay.
Tong S; Chen Q; Shan SQ; Dewhirst MW; Yuan F
Angiogenesis; 2006; 9(2):53-8. PubMed ID: 16622786
[TBL] [Abstract][Full Text] [Related]
5. Characterization of molecular and structural determinants of selective estrogen receptor downregulators.
Fan M; Rickert EL; Chen L; Aftab SA; Nephew KP; Weatherman RV
Breast Cancer Res Treat; 2007 May; 103(1):37-44. PubMed ID: 17033922
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism.
Shiau AK; Barstad D; Radek JT; Meyers MJ; Nettles KW; Katzenellenbogen BS; Katzenellenbogen JA; Agard DA; Greene GL
Nat Struct Biol; 2002 May; 9(5):359-64. PubMed ID: 11953755
[TBL] [Abstract][Full Text] [Related]
7. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.
Celik L; Lund JD; Schiøtt B
Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692
[TBL] [Abstract][Full Text] [Related]
8. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
Wittmann BM; Sherk A; McDonnell DP
Cancer Res; 2007 Oct; 67(19):9549-60. PubMed ID: 17909066
[TBL] [Abstract][Full Text] [Related]
9. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
10. Small-angle X-ray scattering studies on structures of an estrogen-related receptor alpha ligand binding domain and its complexes with ligands and coactivators.
Jin KS; Park JK; Yoon J; Rho Y; Kim JH; Kim EE; Ree M
J Phys Chem B; 2008 Aug; 112(32):9603-12. PubMed ID: 18646811
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.
Dayan G; Lupien M; Auger A; Anghel SI; Rocha W; Croisetière S; Katzenellenbogen JA; Mader S
Mol Pharmacol; 2006 Aug; 70(2):579-88. PubMed ID: 16679488
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.
Arao Y; Hamilton KJ; Coons LA; Korach KS
J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188
[TBL] [Abstract][Full Text] [Related]
13. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.
Weatherman RV; Clegg NJ; Scanlan TS
Chem Biol; 2001 May; 8(5):427-36. PubMed ID: 11358690
[TBL] [Abstract][Full Text] [Related]
14. Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor.
Kojetin DJ; Burris TP; Jensen EV; Khan SA
Endocr Relat Cancer; 2008 Dec; 15(4):851-70. PubMed ID: 18755852
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
16. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
17. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
Maru BS; Tobias JH; Rivers C; Caunt CJ; Norman MR; McArdle CA
Bone; 2009 Jan; 44(1):102-12. PubMed ID: 18976723
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Chakraborty S; Levenson AS; Biswas PK
BMC Struct Biol; 2013 Oct; 13():27. PubMed ID: 24160181
[TBL] [Abstract][Full Text] [Related]
19. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptors as therapeutic targets in breast cancer.
Ariazi EA; Ariazi JL; Cordera F; Jordan VC
Curr Top Med Chem; 2006; 6(3):181-202. PubMed ID: 16515478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
